手握最全产品矩阵 商业化进程全面领跑 人工心脏龙头企业核心医疗上会在即

This article covers CoreHeart Medical, China's leading artificial heart company, which will undergo its Shanghai STAR Market IPO hearing on July 2 to become the world's first publicly listed pure-play artificial heart manufacturer. Key takeaways are as follows:

1. Product and technology: CoreHeart has two commercialized products. Its Corheart 6 is the world's smallest and lightest commercial fully magnetic levitation implantable artificial heart, with over 1,300 cumulative implantations and a 2-year patient survival rate of 86% — outperforming comparable international products. Its CorVad 4.0 is China's first approved interventional artificial heart, with technology reaching global leading standards.

2. Corporate positioning: CoreHeart is the only company in the world to have achieved commercialization for both implantable and interventional artificial hearts. It boasts the industry's most comprehensive product pipeline covering all age groups and full clinical scenarios. From January to May 2025, Corheart 6 held over 52% domestic market share, ranking first in the industry.

3. Industry outlook: The global artificial heart market faces massive unmet demand and is poised for rapid expansion. Following this IPO, CoreHeart will further advance technological innovation and global expansion.

This article provides multi-dimensional insights for innovative medical device brands, as outlined below:

1. R&D direction: Brands can pursue differentiated original technology routes and achieve breakthroughs first by leveraging local market advantages, rather than limiting themselves to following overseas competitors. CoreHeart has broken the global artificial heart market's oligopoly held by foreign players, achieving Chinese leadership rather than simple import substitution, and has built global competitiveness on the back of local advantages.

2. Brand competition strategy: Brands should build a multi-product matrix to establish ecological barriers. CoreHeart's dual layout of implantable and interventional products, covering full clinical scenarios, forms a tiered structure of "flagship leadership + pipeline follow-up", leveraging the reputation of its benchmark product to drive promotion across the entire product matrix, effectively boosting brand influence.

3. Policy and global expansion: Brands should make full use of China's fast-track review and approval pathway for innovative domestic medical devices to shorten time-to-market and capture market share early. Leveraging China's large patient base to accumulate real-world data for domestic validation before expanding globally also helps reduce overseas expansion risks.

This article outlines the growth opportunities, policy dividends and development directions of the artificial heart track. Key insights are as follows:

1. Growth opportunities: There are nearly 63 million heart failure patients worldwide, and a severe shortage of heart transplant donors, creating an enormous gap in clinical demand for artificial hearts. The global implantable artificial heart market is projected to reach $4.08 billion by 2033, with a 14.3% CAGR from 2024 to 2033. In comparison, the global short-to-medium term interventional artificial heart market will reach $9.33 billion over the same period, with an 18.2% CAGR — meaning the interventional segment covers a broader patient base, grows faster and offers larger incremental growth space.

2. Policy dividends: China offers a fast-track review and approval pathway for first-in-China, globally leading innovative medical devices, which effectively shortens product launch timelines and helps companies capture market share early. CoreHeart has more products approved for the fast-track pathway than any other domestic artificial heart player.

3. Development roadmap reference: Companies should first root themselves in the domestic market to complete commercial validation of their products, accumulate real-world data and build market reputation, then leverage the advantage of domestic validation to advance global expansion. CoreHeart already holds the leading domestic market share, has completed prerequisites for globalization and is well positioned to expand overseas.

This article offers valuable insights for medical device manufacturing factories to capture market demand and industry opportunities, as follows:

1. Product design and manufacturing requirements: The artificial heart track has significant unmet clinical demand, with a clear product design direction. Technological breakthroughs are needed around miniaturization, low power consumption, high hemocompatibility, and low adverse event rates, with clear market demand for both long-term implantable products and short-term interventional products for high-risk PCI and cardiogenic shock.

2. Business opportunities: The artificial heart track has high technical and process barriers, with very few companies globally capable of R&D and commercialization. China has now achieved domestic technological leadership in the sector; local companies not only dominate the domestic market but are also starting to expand globally. The large overall growth space of the track brings sufficient incremental business to upstream supporting manufacturing factories.

3. Development insights: Companies can leverage China's large patient base to rapidly complete product validation and technological accumulation, refine product performance gradually before advancing global expansion. At the same time, companies should prioritize technological accumulation, tiered product pipeline布局, and continuous iterative innovation to maintain long-term competitiveness.

This article outlines industry trends and core pain points in the artificial heart track, and provides direction for relevant medical device service providers, as follows:

1. Industry trends: The global artificial heart market is about to enter a period of rapid expansion, with both implantable and interventional products posting double-digit annual compound growth. Interventional products cover a broader range of patients and clinical scenarios, feature a larger market size and faster growth, and will serve as a key growth engine going forward. The track currently has a large supply gap and ample development space.

2. Core customer pain points: For clinical scenarios such as high-risk PCI and cardiogenic shock, traditional treatment protocols have clear limitations, with a large unmet need for products that improve surgical safety and patient survival. Artificial heart companies need to break through bottlenecks in core technologies including magnetic levitation control and micro motors, to solve challenges such as miniaturization and hemolysis.

3. Service direction: Service providers can build布局 around core original technology links, offering technical services for magnetic levitation control and micro motor technology to help companies achieve technological breakthroughs. At the same time, providers can leverage local resources to help companies accumulate real-world clinical evidence and accelerate product review and approval.

This article provides reference for healthcare-related platforms to capture track opportunities and optimize operational布局, as follows:

1. Track demand: The innovative medical device sector, particularly artificial hearts, has already achieved Chinese technological leadership, with large unmet market demand and rapid growth. Leading players have already completed commercial validation and have clear demand for financing and expansion. CoreHealth is set to raise capital via a STAR Market IPO to further advance technological innovation and global expansion.

2. Investment and recruitment opportunities: Platforms should prioritize onboarding innovative medical device companies that own core original technology, have a multi-product matrix布局, and have completed domestic commercial validation. These companies have strong growth potential. CoreHealth, as the world's only artificial heart leader with dual commercialization of implantable and interventional products, has a complete product pipeline, holds the top domestic market share, and boasts outstanding competitiveness.

3. Risk mitigation: The artificial heart track has high technical barriers and long R&D cycles, so platforms should prioritize projects that have been accepted into China's innovative medical device fast-track pathway and completed clinical validation. These projects have shorter time-to-market and faster commercial progress, which effectively reduces platform project risk while delivering value faster.

This article discloses the latest development trends of the artificial heart industry, and provides rich data and insights for industry research, as follows:

1. New industry trends: China's artificial heart industry has carved out a differentiated development path, achieving domestic technological leadership rather than simple import substitution. Local Chinese players have outperformed overseas competitors in product performance through original technological breakthroughs. As the industry leader, CoreHeart is the only company in the world to achieve dual commercialization of implantable and interventional artificial hearts, and is advancing from domestic leadership to global expansion.

2. New changes in market structure: In the global artificial heart market, short-to-medium term interventional products have already outpaced implantable products in both market size and growth rate, becoming the track's new growth engine. China's large domestic patient pool is a unique advantage for Chinese companies, enabling them to accumulate real-world evidence rapidly to support global expansion.

3. Updated summary of competition and policy: China's fast-track review policy for innovative medical devices has effectively accelerated the launch of high-quality innovative products. The competitive logic of the artificial heart track has shifted from single-product breakthrough to multi-product matrix ecological competition; a complete product matrix itself is an important competitive barrier that enhances business resilience.